NCT06676449View on ClinicalTrials.gov

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

PHASE3RecruitingINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

October 31, 2028

Study Completion Date

October 30, 2030

Conditions
Esophageal CarcinomaRadiotherapyImmunotherapy
Interventions
DRUG

Immunotherapy

PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.

DRUG

chemotherapy: Paclitaxel/Cisplatin

Paclitaxel 135mg/m2 d1, cisplatin 25mg/m2 d1-3, once every 3 weeks for 4 cycles.

RADIATION

TDLN-sparing RT

TDLN-sparing radiotherapy 50.4Gy/28Fx.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER